NCT00208299View on ClinicalTrials.gov

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,231

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions

Coronary Artery Disease

Interventions

DRUG

Regadenoson

0.4 mg, bolus intravenous injection

DRUG

Adenosine

0.14 mg/kg/min for 6 minutes, intravenous infusion

Trial Locations (1)

94304

Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Gilead Sciences

INDUSTRY